Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Currently, the BPC-157 peptide is not FDA-approved, and research is ongoing regarding its medical applications
Active cancer is a contraindication for most growth-factor-adjacent peptides because we do not want to fertilize a tumor we do not know about
Patients with musculoskeletal injury, systemic inflammation, or recovery goals outside the GI tract need injectable delivery for reliable systemic bioavailability
A thorough evaluation by an endocrinologist is required before enrollment
Angiogenic Pathway Activation Multiple components contribute to blood vessel formation through distinct but complementary mechanisms: BPC-157 upregulates VEGFR2 expression and enhances endothelial cell proliferation TB-500 promotes endothelial cell migration and tube formation GHK-Cu stimulates angiogenic growth factor expression and vessel maturation Combined effects result in improved tissue vascularization and nutrient delivery Anti-Inflammatory Pathway Modulation The blend provides comprehensive inflammation control through multiple targets: BPC-157 modulates nitric oxide synthesis and reduces pro-inflammatory cytokines TB-500 influences inflammatory mediator expression through cytoskeletal mechanisms GHK-Cu reduces oxidative stress and modulates immune cell function Coordinated effects help resolve inflammation while promoting healing Synergistic Advantage: GLOW Blends multi-pathway approach enables simultaneous activation of cellular migration, matrix synthesis, angiogenesis, and inflammation control
Theres also the chance of developing other autoimmune disorders
US$ 20.98
US$ 24.04
US$ 20.61
